VisionCT 3-D breast specimen-designated computed tomography (CT) system. Image courtesy of Faxitron Bioptics.
July 31, 2018 — Hologic Inc. announced it has completed the acquisition of Faxitron Bioptics, a privately-held leader in digital specimen radiography, for approximately $85 million.
The transaction, which closed July 31, broadens Hologic's Breast Health product portfolio and expands the company's role in the clinical continuum of care for breast cancer patients. Specifically, Faxitron's products and channel will enable Hologic to play a larger role in breast conserving surgery, an adjacent growth market for the company's interventional breast business.
Faxitron markets a broad portfolio of products across major categories including digital specimen radiography, breast lesion localization and sentinel lymph node biopsy. The company sells its products mainly to breast surgeons and pathologists. Faxitron most recently introduced VisionCT, what it calls the world's first 3-D breast specimen-designated computed tomography (CT) system to offer 360-degree images of excised lesions.
Faxitron generated approximately $27 million of revenue in their last fiscal year. The acquisition is expected to be roughly neutral to Hologic's non-GAAP earnings per share for the remainder of fiscal 2018 and fiscal 2019, and is expected to be accretive thereafter.
For more information: www.hologic.com
April 23, 2024 
